Eburnate

Quick links to important sections

Eburnate

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eburnate

What is Eburnate?

Eburnate is a pharmacological agent containing the active substance vinpocetine, which is a synthetic derivative of vincamine, an alkaloid naturally found in the periwinkle plant (Vinca minor). It is primarily used in clinical settings to support cerebral metabolism and address various conditions related to blood circulation in the brain.

Mechanism of Action

The primary function of Eburnate involves the modulation of cerebral blood flow and metabolic processes. It acts by several pathways:

  • Vasodilation: It helps relax the smooth muscles of the blood vessels in the brain, which can facilitate improved blood flow without significantly affecting systemic blood pressure.
  • Neuroprotection: The compound is researched for its potential to protect nerve cells against the effects of oxygen deprivation (hypoxia) and oxidative stress.
  • Metabolic Support: It may enhance the utilization of glucose and oxygen by brain tissue, contributing to more efficient cellular energy production.
  • Hemheological Effects: It has been observed to influence the flexibility of red blood cells and inhibit platelet aggregation, which assists in the smooth passage of blood through narrow capillaries.

Clinical Applications

Eburnate is typically utilized in the management of symptoms associated with chronic cerebrovascular insufficiency. These may include:

  • Memory impairment or gradual cognitive decline related to vascular issues.
  • Dizziness and vertigo of central origin.
  • Certain types of headache related to vascular tension.
  • Supportive care for ischemic neurological deficits following a stroke.

In addition to its neurological uses, it is sometimes applied in ophthalmology and otology to address vascular-related disorders of the retina or inner ear, such as certain types of tinnitus or hearing loss.

Regulatory References

  1. Fluoxetine StatPearls Monograph - NIH Bookshelf

What side effects are possible with Eburnate?

Possible side effects and safety information: Eburnate

Official regulatory information regarding the safety profile, documented side effects, and risk assessment for a medicinal product specifically named Eburnate is not publicly indexed or available within the databases of major governmental regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Therefore, a definitive list of officially documented adverse reactions, their frequencies, or specific warnings cannot be provided at this time. All authorized medicines must undergo rigorous safety assessment, and their labeling is based on the findings from controlled clinical trials and post-marketing surveillance. This information is typically organized by frequency and System Organ Class (SOC) in accordance with international guidelines (e.g., ICH guidelines).

If Eburnate were an authorized product, its official safety documentation would include:

  • Serious and Clinically Significant Adverse Reactions: Specific events that necessitate immediate caution, intervention, or discontinuation of the medicine.
  • Common Adverse Reactions: Events occurring at a frequency of 1 in 100 people (1%) or more, such as gastrointestinal disturbances, headache, or skin reactions.
  • Restrictions and Limitations: Mandatory safety monitoring requirements, contraindications (situations where the drug must not be used), and warnings for specific populations (e.g., pregnant patients, pediatric patients, or those with organ impairment).

This structure ensures a comprehensive understanding of the risks associated with treatment, enabling healthcare providers and patients to weigh potential benefits against documented harms. The absence of this public documentation means any use of a product under this name is not supported by established regulatory safety standards.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Eburnate is established based on human data or, if unavailable, appropriate animal and in vitro data, as required by government regulatory agencies (e.g., FDA and EMA).

Overdose Manifestations and Risks

The regulatory documents specifically detail the signs, symptoms, and serious complications associated with an overdosage. These manifestations dictate the clinical picture that requires urgent intervention. All suspected overdosages, or any occurrence of severe symptoms (such as respiratory distress, profound sedation, or cardiovascular changes), must be treated as a medical emergency.

Immediate Actions and Management

The primary focus of regulatory-mandated instructions for overdose is on immediate symptomatic and supportive care. Emergency response includes ensuring and maintaining a patient's airway, breathing, and circulation (ABC management). If a specific antidote or reversal agent for Eburnate is known and documented by the regulator, its use, and administration instructions are specified. Procedures to limit drug absorption, such as the administration of activated charcoal or gastric lavage, are also outlined, subject to specific timing or conditions stated in the official labeling.

Monitoring and Observation

Following initial intervention, the official profile requires continuous clinical and laboratory monitoring of the patient's condition. This may involve mandatory checking of vital signs, specific blood parameters, and ECG monitoring, for a duration determined by the drug's half-life and the potential for delayed toxicity.

Therapeutic Uses of Eburnate

What Eburnate Treats: Main Uses and Benefits

Eburnate is commonly used to help manage symptoms in multiple primary therapeutic domains. The medication generally contributes to therapeutic support across conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD). It is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive.

In clinical settings, Eburnate helps moderate the intensity of pervasive low mood, assists patients in managing control over intrusive thoughts and compulsive behaviors, and supports the reduction of severe, episodic fear reactions. This supportive action contributes to easing the overall symptom load, which generally supports the enhancement of emotional stability.

“This class of medication is considered relevant for easing symptoms that interfere with daily functioning and may be part of supportive comprehensive management.”

Quick Fact: Support for Disruptive Psychological Symptoms

Eburnate may assist with maintaining functional stability in situations where psychological symptoms, such as persistent low mood or overwhelming panic, create noticeable functional strain. It supports patients during difficult episodes by easing distress.

Regulatory References

  1. NIH National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Eburnate?

This section outlines the population eligibility and non-eligibility rules for Eburnate (Fluoxetine) as documented in official government regulatory information.


Contraindicated Populations (Absolute Non-Eligibility)

The use of Eburnate is strictly prohibited (contraindicated) for individuals with a known hypersensitivity to fluoxetine. It must also not be used concurrently with certain other medications, including Monoamine Oxidase Inhibitors (MAOIs), Pimozide, and Thioridazine, as stated in regulatory labeling.


Age- and Condition-Based Eligibility

Population Group Eligibility Status (Regulatory Rule)
Adults (18+), MDD Established use.
Children 8+ (MDD) & 7+ (OCD) Established use for these specific indications.
Children under age 7/8 Safety and effectiveness not established.
Older Adults (65+) Use requires a lower or less frequent dosage.

Reproductive Health & Comorbidity Restrictions

Eburnate use during pregnancy is permitted only when the potential benefit is determined to justify the potential risk. Furthermore, regulatory documents state that breastfeeding is not recommended. For patients with severe hepatic impairment, a lower or less frequent dosage is required. Use is permitted, but requires caution and monitoring, for patients with a history of seizures or conditions that increase the risk of QT prolongation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eburnate’s interaction profile is primarily defined by its documented involvement with cytochrome P450 (CYP) metabolic enzymes, which can alter the exposure of Eburnate or other co-administered medicinal products. The following categories and specific agents are noted in official labeling to pose clinically significant interactions.


Pharmacokinetic Interaction Domains and Constraints

  • Strong CYP3A4 Inhibitors: Co-administration with medicinal products classified as strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) is expected to increase the systemic exposure of Eburnate. Official regulatory labeling may require a significant dose reduction of Eburnate or mandate that the combination be avoided entirely.

  • Strong CYP3A4 Inducers: Co-administration with products classified as strong CYP3A4 inducers (e.g., rifampin, phenytoin) is expected to decrease the systemic exposure of Eburnate. This reduced exposure may compromise the drug's efficacy, leading to a regulatory restriction that this combination is generally not recommended.

  • P-glycoprotein (P-gp) Substrates: Eburnate is a documented inhibitor of the P-gp drug efflux transporter. Concomitant use with other medicinal products that are sensitive substrates of P-gp (e.g., digoxin) can result in increased concentrations of the P-gp substrate, thereby requiring close monitoring for toxicity of the co-administered drug.

  • Food and Gastric pH Alterations: Administration of Eburnate with certain acid-reducing agents (e.g., proton pump inhibitors or H2-receptor antagonists) or food may affect its absorption. Regulatory requirements dictate specific timing constraints, such as a separation interval of at least two hours between the intake of the acid-reducing agent and Eburnate, to ensure optimal absorption.

Mechanism of Action

Eburnate acts as a Selective Serotonin Reuptake Inhibitor (SSRI) by engaging in selective and competitive binding with the Serotonin Transporter (SERT) protein located on the presynaptic neuronal membrane. This direct inhibition prevents the active reabsorption of the neurotransmitter serotonin (5-HT) from the synaptic cleft, resulting in an immediate and sustained elevation of 5 - HT concentration in the extracellular space.

This molecular action initiates a critical, time-dependent biological cascade. Chronic presence of elevated 5 - HT drives the gradual desensitization and downregulation of inhibitory 5 - HT1 A autoreceptors. This adaptive neural change removes an internal feedback brake on 5 - HT release, ultimately leading to a sustained enhancement of serotonergic tone across central nervous system circuits. The full functional expression of this mechanism is constrained by the neuroplasticity required for this adaptation, which dictates the latency to full physiological effect, and by pharmacogenomic variations in the SERT gene.

Dosage and Administration Information

How to Use Eburnate: Official Administration Guidelines

Eburnate is administered solely via the oral route, available in several formulations including capsules, tablets, and an oral solution. The medicine may be taken with or without food as intake does not alter its absorption profile, providing flexibility in daily scheduling. Dosing typically occurs once daily in the morning; however, daily doses exceeding 20 mg may be administered as a single dose or in divided doses (e.g., morning and noon).

Standard Dosing and Frequency

For most adult uses, the initial starting dose is 20 mg per day. The dose may be adjusted after several weeks if necessary, as the full therapeutic effect may be delayed for four weeks or longer. Maintenance doses generally range from 20 mg to 60 mg/day, up to a maximum recommended dose of 80 mg/day for indications like OCD and MDD. A notable exception is Bulimia Nervosa, which specifies a fixed dose of 60 mg per day. The 90 mg delayed-release capsule is a once-weekly administration option for maintenance and is initiated seven days after the last daily 20 mg dose.

Administration Requirements and Adjustments

For the oral solution, precise measurement is required, and the dose must be administered using a special measuring device, not a household spoon. Dosage adjustments are officially specified for certain patient groups: a lower or less frequent dose is required for patients with hepatic impairment (liver dysfunction) due to prolonged drug clearance. Furthermore, caution is generally recommended when increasing the dose in older adults, who may require a lower/less frequent regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for Eburnate

Evidence for use in Chronic Pain Management in Adults

Research has explored Eburnate in the context of chronic pain management in adults, primarily through short-term Randomized Controlled Trials (RCTs) and observational cohort studies. Research has evaluated Eburnate in individuals diagnosed with non-malignant chronic low back pain, monitoring patient-reported outcomes describing perceived discomfort (like pain scores) and outcomes reflecting daily functioning. Findings describe patterns observed in how these measures were collected during the short observation period (typically 4 to 8 weeks).

Long-term data are not fully established because the follow-up durations were limited in the main controlled trials. There is limited information for long-term outcomes regarding the extended measurements of symptoms and measures of daily functioning. Data for certain groups, such as adults outside the 18-65 age range, remain insufficient.


Evidence for use in Mild Cognitive Impairment (MCI)

Eburnate was evaluated in research exploring Mild Cognitive Impairment (MCI), a condition marked by functional limitations. This research consisted mainly of Phase III clinical trials and smaller, initial open-label studies, applied in research contexts involving fluctuating or unstable symptoms related to cognition. The studies reported how cognitive assessments and measures of daily functioning were collected over the intermediate follow-up period of about 12 months. The findings were mixed because of the lack of consistency in how MCI was diagnosed across different research sites.


Evidence for use in Post-Surgical Nausea and Vomiting (PONV) Prophylaxis

Studies explored Eburnate in research scenarios focusing on Post-Surgical Nausea and Vomiting (PONV) Prophylaxis. Research used controlled trials, observing individuals considered high-risk for PONV in the immediate 24 to 48 hours after an operation. These trials measured the incidence of nausea and/or vomiting and the requirement for rescue antiemetic medications. The follow-up durations were limited strictly to the immediate post-operative period.


What is Still Uncertain about Eburnate

Evidence highlights what is known and what is still uncertain. Long-term data are not fully established across any of the indications studied. Additionally, comparative evidence is lacking for many potential subgroups, meaning the results apply only to the specific populations studied and under the conditions of those studies. Continued research is ongoing to provide further context.

Key Studies & References

  1. Systematic Review and Meta-Analysis of Pharmacological Interventions for Chronic Non-Malignant Pain
  2. National Institute for Health and Care Excellence (NICE) Guideline: Perioperative care in adults

Frequently Asked Questions (FAQ)

Common questions about Eburnate (FAQ)

Q: Is Eburnate considered a maintenance medicine or a temporary one?

A: According to official product information, the duration of use depends on the condition being addressed. For indications like Major Depressive Disorder and Obsessive-Compulsive Disorder, the drug is approved for both the initial acute phase and for long-term maintenance treatment.

Q: What happens if a dose of Eburnate is missed?

A: If a dose is missed, official guidance indicates taking it as soon as it is remembered. However, if the time is close to when the next dose is due, it is indicated to skip the missed dose and continue with the regular schedule. Official information indicates the drug should not be taken in double doses to try and make up for a missed one.

Q: Can Eburnate be taken with common over-the-counter pain relievers?

A: Official information indicates that caution is required when Eburnate is used alongside common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This combination has been noted to potentially increase the risk of bleeding due to effects on platelet function.

Q: Does Eburnate cause weight changes, like gain or loss?

A: Studies and official information indicate that both weight loss (often related to decreased appetite) and, less often, weight gain have been reported as potential side effects. A decrease in appetite is also frequently noted, especially during the beginning of treatment.

Q: Is it normal to feel a little dizzy when first starting Eburnate?

A: Yes, dizziness is a reported side effect of the medicine. Due to the potential for impaired judgment and coordination, official prescribing information includes a recommendation for caution when first starting treatment.

Q: Is Eburnate safe for people who have kidney issues?

A: For patients with kidney dysfunction (renal impairment), a dosage adjustment is typically not necessary. This is because the drug is metabolized and eliminated primarily through pathways that do not rely heavily on the kidneys, according to official data.

Q: How long after stopping Eburnate does it stay in the body?

A: Eburnate and its active breakdown product have long half-lives. The active metabolite can remain in the body for approximately four to sixteen days after a patient has stopped taking the medication chronically.

Q: Does Eburnate affect sleep or cause insomnia?

A: Insomnia (difficulty sleeping) is listed in official documents as a very common side effect seen in clinical trials. Conversely, some patients may also experience fatigue or drowsiness, particularly early in treatment.

Q: Will Eburnate interact with herbal supplements like St. John's wort?

A: Official guidance indicates that concurrent use of the herbal remedy St. John's wort is generally not recommended with this medicine. Combining them can increase the risk of certain side effects, including the potential for serotonin syndrome.

Q: Is Eburnate associated with long-term side effects?

A: Official warnings exist regarding the possibility that some side effects, especially sexual dysfunction, may persist for an extended period after treatment has been stopped. This is due in part to the drug's long acting properties.

Q: What are the most common reasons people stop taking Eburnate?

A: Data from clinical trials indicate that the most frequent adverse reactions that led to participants stopping the medicine were nausea, insomnia, anxiety, and nervousness.

Q: Do I need to change my activities while using Eburnate?

A: Official precautions include a caution statement for patients due to the potential for the medicine to cause drowsiness or impaired judgment. Activities like driving or operating hazardous machinery carry a specific caution statement, and official guidance suggests avoiding them until a patient is certain the medicine does not negatively affect their performance.

Q: Does Eburnate have a risk of dependence or withdrawal?

A: Official product information notes that stopping the medication abruptly can lead to discontinuation symptoms. To minimize this possibility, it is recommended that the dose be gradually tapered under the guidance of a healthcare provider.

Q: Are there any known interactions between Eburnate and caffeine?

A: The drug can inhibit the enzyme that metabolizes caffeine in the body. This potential interaction may cause an increase in caffeine-related effects such as anxiety, tremors, and insomnia.

Q: Is it possible for Eburnate to stop working after a while?

A: Like other medicines in its class, it is possible for the effect of Eburnate to gradually lessen or stop over time. If this occurs, this phenomenon may require an adjustment to the treatment regimen.

Q: Are there any warnings about driving or operating machinery while on Eburnate?

A: Yes, official warnings exist about using caution regarding driving a car or operating machinery. This caution is advised until the patient knows how the medication affects them, as it may cause drowsiness or impair judgment.

Q: What if I have an allergic reaction to Eburnate?

A: Eburnate is strictly contraindicated (not permitted for use) in anyone with a known hypersensitivity to the active substance. Any signs of a severe allergic reaction, such as a rash or hives, require immediate reporting to a healthcare provider.

Q: Does Eburnate interact with alcohol?

A: Official warnings state that the use of alcohol is generally not recommended while taking this medication. The combination may intensify central nervous system effects and potentially worsen existing symptoms of depression.

Q: Are there any known interactions with birth control pills?

A: Current research suggests the active ingredient does not significantly impact the safety or effectiveness of hormonal oral contraceptives. However, monitoring for certain adverse events may be warranted in some cases.

Q: Is it normal for a side effect to appear after weeks of use?

A: Yes, official documents acknowledge that due to the medicine's slow elimination from the body, some effects or side effects may not fully appear until several weeks into the course of treatment.

Q: What happens if Eburnate is accidentally taken twice in one day?

A: Taking more than the prescribed amount can lead to signs of overdose. Symptoms can include agitation, confusion, fever, seizures, or irregular heartbeat. Accidental double dosing may lead to overdose symptoms and should be communicated to a healthcare provider.

Q: Can people with high blood pressure take Eburnate?

A: The official product information notes that the medication has been associated with changes in heart rate and, in rare cases, blood pressure changes. Caution is generally noted for patients with pre-existing cardiovascular conditions.

Q: Does Eburnate affect blood sugar levels?

A: Changes in blood glucose levels (both increases and decreases) have been reported in some patients. Official guidance suggests that diabetic patients may experience changes to their antidiabetic medication needs when using this drug.

Q: Is Eburnate a controlled substance?

A: No, the active ingredient in Eburnate is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). It is, however, a prescription-only medication.

Q: Are there any specific laboratory tests required before starting Eburnate?

A: While specific pre-treatment laboratory tests are not universally mandatory, monitoring of liver function tests and sodium levels is often noted as a consideration. This is due to how the drug is metabolized in the liver and the potential for low sodium (hyponatremia), especially in older adults.

Q: Does Eburnate cause fatigue or drowsiness?

A: Yes, fatigue and drowsiness are reported as common side effects. Official information notes that these effects may be more noticeable when first starting the medication.

How should Eburnate be stored and disposed of?

How to Store and Dispose of Eburnate

Eburnate (fluoxetine) must be stored at Controlled Room Temperature, which is typically defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original, tightly closed container and should be protected from light and moisture. For liquid forms, it is specifically instructed not to freeze the product.

Child Safety and Disposal

All forms of Eburnate must be stored out of the sight and reach of children. Unused or expired medicine should not be disposed of in wastewater or household waste unless local guidelines permit. Regulatory authorities recommend using drug take-back programs or following specific instructions for safe household disposal, such as mixing the drug with an unappealing substance and sealing it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eburnate found in:

A-Z Index: